Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C26648
http://purl.obolibrary.org/obo/NCIT_C26648
|
|---|---|
| Preferred Name | HER2 Inhibitor CP-724,714 |
| Definitions |
An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth. HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable quinazoline with potential antineoplastic activity. CP-724,714 selectively binds to the intracellular domain of HER2, reversibly inhibiting its tyrosine kinase activity and resulting in suppression of tumor cell growth. HER2, a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in many adenocarcinomas, particularly breast cancers. (NCI04) |
|---|---|
| label | HER2 Inhibitor CP-724,714
|
| prefLabel | HER2 Inhibitor CP-724,714
|
| Legacy Concept Name | CP-724_714
|
| in_subset | |
| Preferred_Name | HER2 Inhibitor CP-724,714
|
| Is_Value_For_GDC_Property | |
| Maps_To | HER2 Inhibitor CP-724,714
|
| PDQ_Open_Trial_Search_ID | 285619
|
| UMLS_CUI | C1327906
|
| FDA_UNII_Code | I05QZ0S4V3
|
| prefixIRI | NCIT:C26648
|
| NCI_Drug_Dictionary_ID | 285619
|
| Contributing_Source | FDA
|
| subClassOf | |
| code | C26648
|
| type | |
| ALT_DEFINITION | A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called ErbB receptor tyrosine kinase inhibitors.
|
| PDQ_Closed_Trial_Search_ID | 285619
|
| Semantic_Type | Pharmacologic Substance
|
| CAS_Registry | 383432-38-0
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |